感染症学雑誌
Online ISSN : 1884-569X
Print ISSN : 0387-5911
ISSN-L : 0387-5911
症例
COVID-19 を来した血液透析患者に対してヒドロキシクロロキンを投与した1 例
南 順也肥山 和俊長崎 洋司下野 信行
著者情報
ジャーナル フリー

2020 年 94 巻 4 号 p. 596-599

詳細
抄録

We report the case of a hemodialysis patient diagnosed as having COVID-19. He was emergently transferred to our hospital, which is a designated infectious diseases hospital with facilities for hemodialysis. The pneumonia had progressed steadily until he was transferred to our hospital. However, with the start of hydroxychloroquine sulfate (trade name:Plakenil) administration at our hospital, his condition began to show significant improvement. He was discharged from our hospital on day 19 of admission. Chloroquine has been used for many years as a drug for the treatment and prevention for malaria. In recent years, hydroxychloroquine has been used for the treatment of collagen vascular diseases, such as cutaneous and systemic lupus erythematosus. Chloroquine phosphate was used to treat severe acute respiratory syndrome (SARS) during the 2002-2003 epidemic of the disease. China reported clinical efficacy of chloroquine phosphate for the treatment of COVID-19. Chloroquine has been demonstrated to exert antiviral activity against SARS-CoV-2 in vitro, and is considered to control excessive inflammation in vivo due to its immunomodulatory activity. In our patient reported here, we used the drug at the same dosage as that used for the treatment of cutaneous and systemic lupus erythematosus. Although there remains the possibility that the patientʼs condition improved spontaneously in the natural course of the disease, we consider that hydroxychloroquine may have been effective. There is no established treatment for COVID-19, and numerous empiric treatments have been attempted. There have been few reports from Japan of the use of hydroxychloroquine for the treatment of COVID-19, and further accumulation of cases is necessary.

著者関連情報
© 2020 一般社団法人 日本感染症学会
前の記事 次の記事
feedback
Top